2020
Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors
Coleman EL, Olamiju B, Leventhal JS. Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors. Oncology Reports 2020, 45: 891-898. PMID: 33650659, PMCID: PMC7859912, DOI: 10.3892/or.2020.7911.Peer-Reviewed Original ResearchConceptsSevere cutaneous adverse reactionsTyrosine kinase inhibitorsLife-threatening severe cutaneous adverse reactionsAcute generalized exanthematous pustulosisEpidermal growth factor receptorStevens-Johnson syndromeCutaneous adverse reactionsToxic epidermal necrolysisVascular endothelial growth factorGrowth factor receptorAnaplastic lymphoma kinasePlatelet-derived growth factorAdverse reactionsFibroblast growth factor receptorFactor receptorApplication of TKIsGrowth factorHuman epidermal growth factor receptorKinase inhibitorsGeneralized exanthematous pustulosisPotential cutaneous toxicityEndothelial growth factorExanthematous pustulosisEpidermal necrolysisCutaneous toxicity
2019
The life-threatening eruptions of immune checkpoint inhibitor therapy
Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics In Dermatology 2019, 38: 94-104. PMID: 32197753, DOI: 10.1016/j.clindermatol.2019.10.015.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAcute generalized exanthematous pustulosisSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeToxic epidermal necrolysisManagement of irAEsImmune checkpoint inhibitor therapyCell death ligand 1Generalized exanthematous pustulosisCheckpoint inhibitor therapyCutaneous adverse reactionsDeath ligand 1Life-threatening presentationCell death 1Cytotoxic T lymphocytesLife-threatening eruptionsDermatologic toxicitiesExanthematous pustulosisICPI therapyNeutrophilic dermatosisCheckpoint inhibitorsEpidermal necrolysisAdverse eventsCutaneous eruption